Skip to content
Bored Studies
RecruitingPhase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Corxel Pharmaceuticals · NCT07652047

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · Women only
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
90
US sites recruiting
2
Study start
May 11, 2026
Record last updated
June 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Being studied: CX11; Placebo; CX11

Conditions: Obesity & Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male or female, 18-55 years.
  • BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
  • Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
  • Able to comply with study procedures and reproductive requirements.

Exclusion Criteria

  • Diabetes or obesity due to endocrine/genetic causes.
  • Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
  • Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
  • Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
  • Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.

Recruiting US locations

  • Corxel Investigational site

    Las Vegas, NV 89113

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

  • Corxel Investigational Site

    Austin, TX 78744

    Site contact: Study Director · 201-268-3723 · information.center@corxelbio.com

Study contacts (from the official record)

  • Study coordinator · 201-268-3723 · information.center@corxelbio.com
All weight loss studies in Nevada →
A Study to Evaluate the Safety and Tolerability of Different Doses… (NCT07652047) | Bored Studies